• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Jim Cramer

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.
By JIM CRAMER
Oct 30, 2019 | 08:34 AM EDT
Stocks quotes in this article: MRK, PFE, AGN, BIIB, AMGN, LLY, MCK, BMY, CELG, ABBV, NVS, GSK, AZN, JNJ

Drug stocks have become absurdly valued. I mean downright crazy. You have Merck's (MRK) Keytruda doing $3 billion this quarter, easily on track to be the biggest blockbuster in history. It's at a dang 16 times earnings.

When was the last time Pfizer (PFE) beat the numbers? I can't recall. That's why they had to buy Allergan (AGN) for heaven's sakes. I thought it had to have a shortfall now that Lyrica is off patent. Nope, upside surprise. It gives you a 3.7% yield, ultra safe. Better management. And a 12 PE: Are you kidding me?

Biogen (BIIB) may have a way to stop Alzheimer's. The analysts were all skeptical. Now one by one they are starting to believe. I think they will all be converted in the end because this whole test is being pushed by the FDA. This isn't being driven just by Biogen but there are more holds than buys. We've got a $52 billion company that could be worth double that and nobody cares.

Last night Amgen (AMGN) reported a quarter that didn't require a number cut. I am calling that significant. They are starting to win back share in their important migraine franchise. Aimovig had been the leader and then Lilly (LLY) made in-roads with the drug stores not just the terrible middleman as Amgen did. I was on the phone for hours with McKesson (MCK) to order my Aimovig and when I got through they wouldn't even send it where I wanted it to go. They were horrendous. Now, apparently Aimovig is getting to the drug stores. As the spokesman for the American Migraine Foundation, I can tell you this company is just scratching the surface with this psoriatic arthritis drug, the one that Bristol (BMY) had to give away to close the deal with Celgene (CELG) .

Speaking of Bristol it had a super quarter on its own. I think that the combination with Celgene is going to produces so much money that Bristol can call its own shots. I know it has spiked but it still yields 3% and sells for only 12 times earnings. The deal with Celgene could close in December and numbers go up huge.

AbbVie (ABBV) hasn't reported yet but I am confident the numbers will be good but more important the merger with the under-managed Allergan will be amazing. No I am not worried about Botox challengers. I am excited about its pill for migraines. The acute care for migraine is a brand new concept and there are millions of sufferers. It could be gigantic.

Novartis (NVS) is under pressure for tampering with a drug of a company it bought. That will be solved and when it is we will be talking about how crazy it is that this amazing company, led by a doctor, sells at just 17 times earnings.

Glaxo (GSK) ? The change toward a more scientific, long-term pharm company is working.

Lilly? Got hit over some glitch in diabetes. It is coming right back.

AstraZeneca (AZN) ? Some worried that their cancer franchise was chimerical. It's the opposite. I love it although post the move I can take a pass.

Which leaves the real anomaly: Johnson & Johnson (JNJ) . This company has ceased being a pharma enterprise. It is now a law firm. It has become ridiculous. Last night's revelation that the company can't find asbestos in the lots of talc that it tested - the same tests that the FDA did - begs the question: who do you trust? JNJ didn't do the tests. A third party did. I am banking on JNJ. But there's opioids. There's Talc. There's the plaintiff's bar. There's the media. It's the hardest own in the book. That said, this too shall pass. It has tested me like no other and I find it worth owning if you know how to take pain.

If you can't stay away.

My main point? These are too cheap. They are being priced for an Elizabeth Warren win. If she loses? You can see one of the biggest moves this group has had since President Clinton gave up on price controls in the nineties.

Pick one. Pick two. They are priced for total imperfection. That's just what you want. That's just what you get.

(AbbVie, Novartis and Johnson & Johnson are holdings in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells these stocks? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Action Alerts PLUS, which Cramer co-manages as a charitable trust, is long  ABBV, NVS, JNJ.

TAGS: Mergers and Acquisitions | Drug Approvals | Investing | Markets | Stocks | Trading | Pharmaceuticals | Jim Cramer |

More from Jim Cramer

Jim Cramer: This GameStop Nonsense Has Gotten Out of Hand

Jim Cramer
Feb 26, 2021 7:11 AM EST

It has become the market equivalent of the storming of the Capitol, and the viciousness must stop.

Jim Cramer: The Bond Market Vigilantes Strike

Jim Cramer
Feb 25, 2021 1:41 PM EST

What does that mean for stocks? Consider Nvidia.

Jim Cramer: How Do You Pull Off What GameStop Buyers Did?

Jim Cramer
Feb 25, 2021 6:12 AM EST

Here's my theory on how this was done.

Jim Cramer: Don't Miss This Train

Jim Cramer
Feb 22, 2021 2:40 PM EST

We're headed to Boom Town, so let me show you how to line up your ticket -- and the best picks for the great reopening.

Jim Cramer: Toast, the Next Big Thing? I Question its Valuation

Jim Cramer
Feb 22, 2021 6:19 AM EST

Maybe it will be viewed as the ultimate 'opening' story because restaurants might soon come back.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:32 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Navigating a Market Correction
  • 11:29 AM EST GARY BERMAN

    Where Does the Nasdaq Go From Here?

    Where does the Nasdaq Composite (CCMP) index go fr...
  • 12:31 PM EST GARY BERMAN

    Has the Short-Term Top Come for the XLF/Banks?

    The has triggered a long-term overbought signal ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login